Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181818 · ClinicalTrials.gov registry record · Phase 4
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
A Phase 4 study of Cardiovascular Disease and Smoking, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
- 1
- Study location
NCT00181818: Completed Phase 4 study of Cardiovascular Disease and Smoking, sponsored by Massachusetts General Hospital.
NCT00181818 is a Phase 4 study of Cardiovascular Disease and Smoking that has completed, run by Massachusetts General Hospital. The registered enrollment target is 248 participants, below the 2,696-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181818, a Phase 4 study of Cardiovascular Disease and Smoking, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test the efficacy and safety of bupropion SR for smokers hospitalized with acute cardiovascular disease.
Conditions Studied
Interventions
- DRUG bupropion SR (sustained-release)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 1999-10 |
| Est. Completion | 2003-12 |
| Phase | Phase 4 |
What the finished NCT00181818 record still lists
NCT00181818 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 2,696-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which bupropion SR (sustained-release) is the first listed.
NCT00181818 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00181818 about?
NCT00181818 is a clinical study titled "Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease". The purpose of the study is to test the efficacy and safety of bupropion SR for smokers hospitalized with acute cardiovascular disease.
What is the current status of trial NCT00181818?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 1999-10. Estimated completion is 2003-12.
What conditions does trial NCT00181818 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Smoking, Myocardial Infarction, Unstable Angina.
What interventions are being tested in trial NCT00181818?
The interventions under investigation include: bupropion SR (sustained-release) (DRUG).
Who is sponsoring clinical trial NCT00181818?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00181818 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00181818's enrollment target sits among peer trials
248 45th of 137 higher than 93 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
RECRUITING · Phase 4
-
Randomized Trial of SGLT2i in Heart Transplant Recipients
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
MIcrovascular dysfuNction In Moderate-severe Psoriasis
COMPLETED · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia